Beran Rose

Beran is leading the commercialization of a breakthrough product for the treatment of emphysema, the Zephyr Valve. In his tenure with Pulmonx, Zephyr Valves have had 4 RCTs published, been included in global and national treatment guidelines, won reimbursement across Europe, gained FDA approval, and seen rapid growth. At Pulmonx he has forged close relationships with thought leaders and specialty societies to train physicians and raise awareness of this new treatment option, and is now testing Direct to Patient communications in select markets to reach patients not currently managed by specialists.

Prior to Pulmonx, Beran spent close to two decades in market, strategy and business development roles with Boston Scientific and in management consulting. He holds an MBA from MIT Sloan and a BA from Yale University.